Your browser doesn't support javascript.
Impaired response to first SARS-CoV-2 dose vaccination in myeloproliferative neoplasm patients receiving ruxolitinib.
Guglielmelli, Paola; Mazzoni, Alessio; Maggi, Laura; Kiros, Seble Tekle; Zammarchi, Lorenzo; Pilerci, Sofia; Rocca, Arianna; Spinicci, Michele; Borella, Miriam; Bartoloni, Alessandro; Rossolini, Gian Maria; Annunziato, Francesco; Vannucchi, Alessandro M.
  • Guglielmelli P; Department of Experimental and Clinical Medicine, and Center Research and Innovation of Myeloproliferative Neoplasms (CRIMM), University of Florence, Careggi University Hospital, Florence.
  • Mazzoni A; Department of Experimental and Clinical Medicine, University of Florence, and Flow Cytometry Diagnostic Center and Immunotherapy (CDCI), Careggi University Hospital, Florence, Italy.
  • Maggi L; Department of Experimental and Clinical Medicine, University of Florence, and Flow Cytometry Diagnostic Center and Immunotherapy (CDCI), Careggi University Hospital, Florence, Italy.
  • Kiros ST; Department of Experimental and Clinical Medicine, University of Florence, and Microbiology and Virology Unit, Careggi University Hospital, Florence, Italy.
  • Zammarchi L; Department of Experimental and Clinical Medicine, University of Florence, and Infectious and Tropical Diseases Unit, Careggi University Hospital, Florence, Italy.
  • Pilerci S; Department of Experimental and Clinical Medicine, and Center Research and Innovation of Myeloproliferative Neoplasms (CRIMM), University of Florence, Careggi University Hospital, Florence.
  • Rocca A; Department of Experimental and Clinical Medicine, University of Florence, and Microbiology and Virology Unit, Careggi University Hospital, Florence, Italy.
  • Spinicci M; Department of Experimental and Clinical Medicine, University of Florence, and Infectious and Tropical Diseases Unit, Careggi University Hospital, Florence, Italy.
  • Borella M; Department of Experimental and Clinical Medicine, and Center Research and Innovation of Myeloproliferative Neoplasms (CRIMM), University of Florence, Careggi University Hospital, Florence.
  • Bartoloni A; Department of Experimental and Clinical Medicine, University of Florence, and Infectious and Tropical Diseases Unit, Careggi University Hospital, Florence, Italy.
  • Rossolini GM; Department of Experimental and Clinical Medicine, University of Florence, and Microbiology and Virology Unit, Careggi University Hospital, Florence, Italy.
  • Annunziato F; Department of Experimental and Clinical Medicine, University of Florence, and Flow Cytometry Diagnostic Center and Immunotherapy (CDCI), Careggi University Hospital, Florence, Italy.
  • Vannucchi AM; Department of Experimental and Clinical Medicine, and Center Research and Innovation of Myeloproliferative Neoplasms (CRIMM), University of Florence, Careggi University Hospital, Florence.
Am J Hematol ; 96(11): E408-E410, 2021 11 01.
Article in English | MEDLINE | ID: covidwho-1332932
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pyrazoles / COVID-19 Vaccines / Myeloproliferative Disorders Topics: Vaccines Limits: Humans Language: English Journal: Am J Hematol Year: 2021 Document Type: Article

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pyrazoles / COVID-19 Vaccines / Myeloproliferative Disorders Topics: Vaccines Limits: Humans Language: English Journal: Am J Hematol Year: 2021 Document Type: Article